These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20601020)

  • 1. Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.
    Authier S; Pugsley MK; Troncy E; Curtis MJ
    J Pharmacol Toxicol Methods; 2010; 62(2):83-8. PubMed ID: 20601020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quickly finding a needle in a haystack: a new automated cardiac arrhythmia detection software for preclinical studies.
    Koeppel F; Labarre D; Zitoun P
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):92-7. PubMed ID: 22554864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database.
    Green CL; Kligfield P; George S; Gussak I; Vajdic B; Sager P; Krucoff MW
    Am Heart J; 2012 Mar; 163(3):365-71. PubMed ID: 22424006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative TQT analysis with three fully-automated platforms: comparison to core laboratory semi-automated results.
    Meyer O; Greig G; Holzgrefe HH
    J Electrocardiol; 2013; 46(6):717.e1-9. PubMed ID: 23849958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the precision of QT measurements.
    Darpo B; Fossa AA; Couderc JP; Zhou M; Schreyer A; Ticktin M; Zapesochny A
    Cardiol J; 2011; 18(4):401-10. PubMed ID: 21769821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
    Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward.
    Darpo B; Garnett C; Benson CT; Keirns J; Leishman D; Malik M; Mehrotra N; Prasad K; Riley S; Rodriguez I; Sager P; Sarapa N; Wallis R
    Am Heart J; 2014 Sep; 168(3):262-72. PubMed ID: 25173536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical ECG Assessment.
    Darpo B
    Handb Exp Pharmacol; 2015; 229():435-68. PubMed ID: 26091650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.
    Sethuraman V; Sun Q
    Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.
    Natekar M; Mahajan V; Satra A; O'Kelly M; Karnad DR
    Clin Pharmacol Ther; 2008 Mar; 83(3):489-91. PubMed ID: 18183035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
    Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
    J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies.
    Fosser C; Duczynski G; Agin M; Wicker P; Darpo B
    Clin Pharmacol Ther; 2009 Nov; 86(5):503-6. PubMed ID: 19339965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies.
    Guth BD; Bass AS; Briscoe R; Chivers S; Markert M; Siegl PK; Valentin JP
    J Pharmacol Toxicol Methods; 2009; 60(2):107-16. PubMed ID: 19470407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.
    Cavero I; Holzgrefe H; Clements M
    J Pharmacol Toxicol Methods; 2016; 80():1-8. PubMed ID: 26903171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
    Pugsley MK; Curtis MJ; Hayes ES
    Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.
    Chiang AY; Mallinckrodt CH; Dmitrienko AA; Leishman DJ
    J Pharmacol Toxicol Methods; 2010; 62(2):143-7. PubMed ID: 20570744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT Liability.
    Lester RM; Engel C; van Haarst AD; Paglialunga S
    Clin Pharmacol Ther; 2024 Jul; 116(1):42-51. PubMed ID: 38698592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.